Translating RXC007 preclinical antifibrotic efficacy to Ph2a PoC in IPF
Time: 9:30 am
day: Conference Day Two
Details:
- Summarising RXC007 in vivo antifibrotic activity across preclinical rodent fibrosis models
- Presentation of RXC007 Ph2a anti-fibrotic signals in Ph2a IPF trial
- Exploratory circulating biomarkers in IPF and presentation of RXC007 changes
